Valiant Organics Ltd
Incorporated in 1984, Valiant Organics
Ltd manufactures and deals in specialty chemicals and pharma intermediates[1]
- Market Cap ₹ 798 Cr.
- Current Price ₹ 285
- High / Low ₹ 508 / 195
- Stock P/E 26.5
- Book Value ₹ 249
- Dividend Yield 0.00 %
- ROCE 6.21 %
- ROE 4.44 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.14 times its book value
Cons
- The company has delivered a poor sales growth of 5.16% over past five years.
- Company has a low return on equity of 0.97% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 | 52 | 73 | 121 | 606 | 584 | 574 | 948 | 912 | 677 | 719 | 738 | |
| 48 | 36 | 55 | 94 | 426 | 410 | 417 | 783 | 782 | 638 | 665 | 650 | |
| Operating Profit | 11 | 16 | 18 | 26 | 179 | 174 | 157 | 165 | 130 | 39 | 54 | 88 |
| OPM % | 19% | 30% | 25% | 22% | 30% | 30% | 27% | 17% | 14% | 6% | 7% | 12% |
| 1 | 1 | 2 | 1 | 5 | 5 | 17 | 6 | 8 | 9 | 8 | 13 | |
| Interest | 1 | 0 | 0 | 0 | 2 | 1 | 3 | 6 | 11 | 19 | 24 | 18 |
| Depreciation | 1 | 1 | 2 | 2 | 12 | 13 | 19 | 27 | 28 | 34 | 36 | 40 |
| Profit before tax | 11 | 16 | 18 | 25 | 171 | 165 | 152 | 137 | 100 | -5 | 2 | 43 |
| Tax % | 34% | 35% | 35% | 35% | 29% | 25% | 25% | 25% | 24% | -41% | 224% | 20% |
| 7 | 10 | 12 | 16 | 121 | 124 | 115 | 103 | 76 | -3 | -3 | 34 | |
| EPS in Rs | 103.86 | 14.03 | 15.92 | 13.97 | 103.65 | 51.00 | 42.20 | 37.91 | 27.83 | -1.10 | -1.07 | 12.26 |
| Dividend Payout % | 50% | 71% | 16% | 23% | 6% | 11% | 12% | 9% | 4% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 5% |
| 3 Years: | -7% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | -23% |
| 3 Years: | -25% |
| TTM: | 1108% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -29% |
| 3 Years: | -19% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.36 | 4 | 4 | 6 | 6 | 12 | 27 | 27 | 27 | 28 | 28 | 28 |
| Reserves | 21 | 19 | 42 | 53 | 254 | 374 | 475 | 576 | 638 | 637 | 634 | 669 |
| 8 | 1 | 1 | 1 | 53 | 119 | 150 | 306 | 220 | 216 | 212 | 219 | |
| 11 | 17 | 23 | 36 | 89 | 125 | 154 | 174 | 220 | 262 | 206 | 215 | |
| Total Liabilities | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,079 | 1,131 |
| 11 | 12 | 26 | 31 | 130 | 256 | 478 | 509 | 610 | 630 | 644 | 683 | |
| CWIP | 1 | 0 | 0 | 0 | 66 | 129 | 46 | 110 | 70 | 86 | 66 | 21 |
| Investments | 2 | 2 | 7 | 7 | 20 | 34 | 42 | 53 | 53 | 54 | 54 | 64 |
| 26 | 26 | 35 | 58 | 187 | 210 | 240 | 410 | 373 | 371 | 315 | 364 | |
| Total Assets | 40 | 41 | 69 | 96 | 402 | 629 | 806 | 1,083 | 1,106 | 1,142 | 1,079 | 1,131 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 18 | 9 | 18 | 77 | 160 | 115 | -11 | 183 | 85 | 59 | 44 | |
| -1 | -1 | -1 | -6 | -88 | -191 | -135 | -120 | -91 | -65 | -27 | -39 | |
| -5 | -16 | -4 | -5 | 2 | 35 | 22 | 146 | -109 | -23 | -28 | -11 | |
| Net Cash Flow | -0 | 0 | 4 | 7 | -8 | 5 | 1 | 14 | -17 | -3 | 4 | -6 |
| Free Cash Flow | 5 | 16 | 5 | 11 | -6 | -42 | -37 | -126 | 96 | 20 | 29 | 11 |
| CFO/OP | 89% | 150% | 87% | 97% | 69% | 115% | 94% | 10% | 154% | 220% | 109% | 47% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 71 | 88 | 112 | 73 | 69 | 74 | 97 | 85 | 113 | 88 | 120 |
| Inventory Days | 42 | 36 | 97 | 44 | 45 | 47 | 85 | 58 | 69 | 104 | 71 | 76 |
| Days Payable | 7 | 50 | 130 | 154 | 80 | 97 | 135 | 76 | 100 | 189 | 117 | 102 |
| Cash Conversion Cycle | 110 | 57 | 55 | 2 | 37 | 20 | 25 | 80 | 54 | 28 | 43 | 95 |
| Working Capital Days | 53 | 59 | 69 | 41 | 51 | 21 | 4 | 9 | 4 | -7 | -16 | 18 |
| ROCE % | 43% | 61% | 52% | 48% | 91% | 41% | 27% | 18% | 12% | 1% | 3% | 6% |
Insights
In beta| Mar 2021 | Mar 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|
| Total Production Capacity TPA |
|
|||
| Gross Current Assets (GCA) Days Days |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23h - Please find attached our intimation on the captaioned subject
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 1d
-
Corrigendum To The Outcome Of The Board Meeting - May 19, 2026
1d - Corrigendum clarifies DVLLP cessation settlement: 1,86,07,531 Valiant Laboratories shares and Rs. 6.34 crore.
-
Board Meeting Outcome for Outcome Of The Board Meeting
19 May - Board approved exit from DVLLP; 1,86,07,531 Valiant Laboratories shares to settle the amount.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 May - Please find attached the intimation w.r.t. publication of financial results in the newspapers.
Annual reports
Concalls
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Dec 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Mar 2022TranscriptAI SummaryPPT
-
Mar 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Sep 2021TranscriptAI SummaryPPT
Business Overview:[1][2][3]
VOL is is promoted by Gogri, Chedda and Gala families. It manufactures specialty chemicals and is one of the largest manufacturers of chlorophenol derivatives, Benzene derivatives, PNA, PAP, Ortho Anisidine and Para Anisidine.
Product Portfolio[4]
1. Ammonolysis
Products include Para Nitro Aniline and Ortho Chloro Para Nitro Aniline, primarily serving the dyes and pigments industries.
2. Hydrogenation
The product range comprises Ortho Anisidine, Para Anisidine, IPPCA, Meta Chloro Aniline, Para Amino Phenol, and Ortho Amino Phenol, catering to dyes, pigments, pharmaceuticals, and agrochemicals sectors.
3. Chlorination
Key products are Para ChloroPhenol (PCP), Ortho ChloroPhenol (OCP), 2,4 Di ChloroPhenol (2,4 DCP), 2,6 Di ChloroPhenol (2,6 DCP), and 2,4,6 Tri ChloroPhenol (2,4,6 TCP), widely used in agrochemicals, cosmetics, veterinary, and pharmaceutical applications.